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The diagnosis of bloodstream infections (BSIs) still relies on blood culture (BC), but
low turnaround times may hinder the early initiation of an appropriate antimicrobial
therapy, thus increasing the risk of infection-related death. We describe a direct and
rapid multiplex PCR-based assay capable of detecting and identifying 16 bacterial
and four Candida species, as well as three antibiotic-resistance determinants, in
uncultured samples. Using whole-blood samples spiked with microorganisms at low
densities, we found that the MicrobScan assay had a mean limit of detection of
15.1 ± 3.3 CFU of bacteria/Candida per ml of blood. When applied to positive BC
samples, the assay allowed the sensitive and specific detection of BSI pathogens,
including blaKPC-, mecA-, or vanA/vanB-positive bacteria. We evaluated the assay using
prospectively collected blood samples from patients with suspected BSI. The sensitivity
and specificity were 86.4 and 97.0%, respectively, among patients with positive BCs for
the microorganisms targeted by the assay or patients fulfilling the criteria for infection.
The mean times to positive or negative assay results were 5.3 ± 0.2 and 5.1 ± 0.1 h,
respectively. Fifteen of 20 patients with MicrobScan assay-positive/BC-negative samples
were receiving antimicrobial therapy. In conclusion, the MicrobScan assay is well suited
to complement current diagnostic methods for BSIs.
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INTRODUCTION
Early diagnosis of bloodstream infections (BSIs), including those caused by bacteria and fungi, is
central to reducing drastic infection-related consequences, such as significant risks of morbidity
and mortality (Goto and Al-Hasan, 2013; Andes et al., 2016; Seymour et al., 2017). Global estimates
show that in high-income countries, the incidence rates for sepsis and severe sepsis cases were 437
and 270 per 100,000 person-years, respectively, with hospital mortality rates of 17.0% for sepsis and
26.0% for severe sepsis during the last decade (Fleischmann et al., 2016). In the United States, the
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incidence of patients receiving treatment for septic shock rose
from 12.8 to 18.6 cases per 1,000 hospitalizations over 10 years,
while mortality declined from 54.9 to 50.7% (Kadri et al., 2017).
In a recent study, a delay of 50.0min for blood culture (BC) or
125.0min for antibiotic therapy within the 3-h Surviving Sepsis
Campaign guideline increased the risk of death in patients with
severe sepsis and septic shock (Pruinelli et al., 2018).
The reference standard for the microbiological diagnosis of
a BSI is still an automated BC system (Baron et al., 2013).
However, despite the good analytical sensitivity of the BCmethod
(limit of detection [LOD], 1–10 CFU/ml) (Yagupsky and Nolte,
1990; Pfeiffer et al., 2011), slow turnaround time (TAT) is the
main limitation (Lamy et al., 2016), which necessitates the
aggressive empirical usage of antimicrobial agents (Banerjee
et al., 2016; Timbrook et al., 2017). Furthermore, delays in
optimal antimicrobial therapy may drive poor health care quality
as well as increase antimicrobial resistance (Zasowski et al.,
2016; Whiles et al., 2017). Early initiation and modification of
appropriate antimicrobial therapy depends on the availability of
diagnostic methods with rapid TATs, e.g., within 6–8 h of septic
patient presentation (Ginn et al., 2017). Molecular detection
methods applied to positive BCs or direct blood samples show
promise in accelerating microbial identification and predicting
antimicrobial susceptibility (Dubourg and Raoult, 2016; Peker
et al., 2018). It is imperative that diagnostic tests are tailored to
the clinical problem at hand to maximize the cost-effectiveness
of clinical decision-making (Pliakos et al., 2018).
Commercially available methods performed directly on
whole-blood samples include nucleic amplification-based
methods and, only recently, T2 magnetic resonance-based
FIGURE 1 | MicrobScan assay workflow.
methods (Peker et al., 2018). Alternatively, a plasma
metagenomics-sequencing assay (Karius, Redwood City,
CA) generates sequences of circulating microbial cell-free
DNA to enable the non-invasive diagnosis of infectious
diseases (Blauwkamp et al., 2019). Compared to post-culture
detection (e.g., by FilmArray R© Blood Culture Identification
Panel; bioMérieux, Marcy-l’Étoile, France), direct detection
(from blood) eludes the “test method-related” shortcomings
that may lead to false-negative diagnoses because of slow
or not growing microorganisms and cases when the patient
has already received antimicrobials (Farrell et al., 2013). For
example, the LightCycler R© SeptiFast (Roche Molecular System,
Switzerland; www.molecular.roche.com) is a Conformité
Européenne (CE)-marked multiplex real-time PCR (qPCR)
assay that simultaneously detects and identifies DNA from 19
bacterial and 6 fungal species. In a subsequent run, the test
assesses the presence of methicillin resistance in Staphylococcus
aureus-positive samples (Peker et al., 2018). Importantly, the
recent finding of significant rates of false positive (up to 20% or
higher) and false negative (up to 14%) results has limited the
utility of the LightCycler R© SeptiFast as a standalone test (Ginn
et al., 2017). However, multiplex qPCR assays may offer several
advantages (e.g., high-throughput and quantification) (Bustin
et al., 2009), making them well suited to the clinical setting
(Farrell et al., 2013).
We developed a multiplex qPCR-based detection molecular
assay (hereafter designated the MicrobScan assay) that can
process a wide range of microorganism densities (CFU/ml)
directly from blood samples (Figure 1). Specifically, we tested
the general capabilities of this assay using low-density spikes of
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phenotypically characterized and culture-quantified bacterial or
Candida species in blood. By processing samples from a positive
blood culture bottle (PBCB) without measuring the density, we
show that the assay allows the sensitive and specific identification
of 20 frequently encountered microbial pathogens and relevant
antimicrobial resistance genes. Finally, we evaluated the clinical
performance of the assay with blinded whole-blood samples from
patients with suspected BSI.
MATERIALS AND METHODS
Description of the MicrobScan Assay
We designed the MicrobScan assay to run on a fully automated
SepsiScan instrument (Nurex S.r.l., Sassari, Italy), where a
robot can handle 24 samples in parallel. The assay requires
minimal hands-on time (e.g., typically <15min) from putting
the sample into a microwell strip to loading the strip onto
the BioRad CFX Thermal Cycler (BioRad, Hercules, CA, USA),
which is a PCR system for gene amplification. We installed the
SepsiScan instrument at the clinical microbiology laboratory of
the Fondazione Policlinico Universitario A. Gemelli IRCCS of
Rome (Italy), where it automatically completed all assay steps
in prefilled wells starting from 100 µl of the original sample
(i.e., EDTA whole blood). Specifically, the procedural steps that
are automated by the SepsiScan instrument are as follows:
detergent lysis of blood cells; concentration of cellular debris
and microbial cells; extraction of microbial DNA for use as a
template in the multiplex qPCRs (see below); and finally bleach
decontamination of all liquids on the SepsiScan instrument
rack. In particular, DNA extraction is achieved through the
sequential action of lytic enzymes (lysozyme, lyticase, chitinase,
and proteinase K) and strong detergents (including sodium
dodecyl sulfate) and the subsequent purification by binding the
extracted DNA to magnetic beads. After alternate guanidine
thiocyanate/ethanol washing, microbial DNA is eluted from
the beads in 150-µl elution buffer (Tris-EDTA plus 1% Triton
X-100), concentrated in a microfluidic extraction cartridge,
and immediately dispensed in an 8-well strip containing dried
PCR reagents. The entire process enables users to avoid any
contamination by hemoglobin, iron, and any blood-cell PCR
inhibitor. The assay allows for the simultaneous detection and
identification of 20 bacterial/Candida species and 3 antibiotic
resistance-associated genes. We chose the 20 microorganisms,
with or without any antibiotic-resistance determinant, as
molecular targets for the MicrobScan assay based on their
prevalence in clinical laboratory BC assays. The MicrobScan
assay has recently received CE marking.
Growth and Quantification of
Microorganisms
The microorganisms used in this study were well-characterized
bacteria and Candida strains obtained from the ATCC R©
(Manassas, VA, USA) and/or clinical isolates obtained from the
aforementioned clinical microbiology laboratory. In addition
to clinical isolates (N = 333), the ATCC R© strains included
Acinetobacter baumannii (19606TM), Aspergillus fumigatus
(13073TM), Bacteroides fragilis (25285TM), Burkholderia
cepacia (25416TM), Candida albicans (10231TM), Candida
glabrata (2001TM), Candida krusei (6258TM), Candida
orthopsilosis (20503TM), Candida parapsilosis (7330TM), Candida
tropicalis (13803TM), Corynebacterium striatum (BAA-1293TM),
Corynebacterium ramosum (25582TM), Cryptococcus neoformans
(32045TM), Enterobacter aerogenes (13048TM), Enterobacter
cloacae (13047TM), Escherichia coli (25922TM, BAA-2340TM),
Enterococcus faecalis (29212TM, 51299TM), Enterococcus
faecium (55593TM, 700221TM), Haemophilus influenzae
(9006TM), Klebsiella oxytoca (700324TM), Klebsiella ozaenae
(25926TM), Klebsiella pneumoniae (13883TM, BAA-1705TM),
Legionella pneumophila (33152TM), Moraxella catarrhalis
(25238TM), Neisseria meningitidis (13098TM), Pseudomonas
aeruginosa (27853TM), Proteus mirabilis (7002TM), Proteus
vulgaris (13315TM), Serratia marcescens (8100TM), S. aureus
(29213TM, 43300TM), Staphylococcus epidermidis (12228TM,
35984TM), Staphylococcus haemolyticus (29970TM), Staphylococcus
hominis (700586TM), Stenotrophomonas maltophilia (13637TM),
Streptococcus agalactiae (12403TM), Streptococcus pneumoniae
(6305TM), Streptococcus pyogenes (12344TM), Streptococcus
parasanguinis (31412TM), and Streptococcus salivarius (25975TM).
We grew all the microbes on appropriate agar media to
harvest single colonies, which were diluted 10-fold at various
concentrations in sterile phosphate-buffered saline and then
quantified by culture onto the media to estimate the CFU
per milliliter.
Primer and Taqman Probe Selection
We detected 20 clinically relevant microorganisms using species-
or group-specific target genes as follows: bap gene for A.
baumannii (De Gregorio et al., 2015); leuB gene for B. fragilis
(Papaparaskevas et al., 2013); 5.8S rRNA gene for C. albicans;
internal transcribed spacer 1 (ITS1), 5.8S rRNA, and ITS2 genes
for C. glabrata and C. krusei (Metwally et al., 2007); 18S rRNA
gene for Candida spp.; omp35 gene for E. aerogenes (van der
Zee et al., 2016); apbC gene (formerly referred to as unknown
gene) for E. cloacae complex (van der Zee et al., 2016); 16S rRNA
gene for E. coli (van den Brand et al., 2014); groESL gene for
E. faecalis and E. faecium (Fukumoto et al., 2015); rhaA-rhaD
operon gene for Klebsiella spp. (van den Brand et al., 2014); phzE
gene for P. aeruginosa (van den Brand et al., 2014); hns gene for
P. mirabilis (van der Zee et al., 2016); gyrB gene for S. marcescens
(van den Brand et al., 2014); spa gene for S. aureus; tuf gene for
Staphylococcus spp. (van den Brand et al., 2014); lytA gene for
S. pneumoniae (Gadsby et al., 2015); sdaB gene for S. pyogenes
(Fukumoto et al., 2015); and the 16S rRNA gene for Streptococcus
species. Additionally, we detected three antibiotic-resistance
genes, including the blaKPC carbapenemase gene (Zheng et al.,
2013), the mecA methicillin resistance gene (Thomas et al.,
2007), and the vanA/vanB vancomycin resistance genes. Finally,
we used the human RNase gene as an internal control for
sample DNA.Unless otherwise specified, we selected primer pairs
and Taqman probes from conserved regions of the respective
specific sequences using Beacon DesignerTM software (Premier
Biosoft, Palo Alto, CA, USA). To test for any potential cross-
reactivity, we performed in silico specificity studies to compare
the oligonucleotide sequences to all known genetic sequences.
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Multiplex qPCR System
The MicrobScan assay consists of seven parallel qPCRs in
seven reaction wells, including 1 duplex, 3 triplex, and 3
quadruplex reaction wells, which target the 20 microorganisms
and 3 antibiotic-resistance determinants per sample. Another
well serves as an RNase gene-based control. We optimized the
qPCRs by testing different concentrations of each primer pair and
Taqman probe, as well as buffer components, and we calculated
PCR efficiencies from the slopes of standard curves that were
run in triplicate (data not shown). The final 30-µl qPCR mixture
contained deoxynucleoside triphosphates (including dUTP) and
uracil-N-glycosylase. We used concentrations of 400 nM for all
primer pairs and 150 nM for all probes. We carried out qPCRs
using the aforementioned BioRad CFX Thermal Cycler using the
following thermal cycling conditions: an initial denaturation step
at 95◦C for 10min, followed by 40 cycles of 94◦C for 15 s and
60◦C for 30 s. We ran positive (DNA mixtures of all the targets)
and negative (sterile water) PCR controls in qPCRs for each test
sample batch.We analyzed qPCR data using proprietary software
(Nurex S.r.l.) designed ad hoc to generate a quantification cycle
(Cq) (formerly referred to as threshold cycle [Ct]) (Bustin et al.,
2009) value for each of the targets. Based on our experiments with
spike-in controls, a Cq value of 40 was set up as a cutoff value for
positivity, and we considered a sample as positive if the Cq value
was ≤40. We based the differentiation between S. aureus and
one Staphylococcus species, between S. pneumoniae/S. pyogenes
and one Streptococcus species and between C. albicans and one
Candida species on the results of two corresponding qPCRs,
respectively. If both qPCRs were positive, we identified the
microorganism(s) as belonging to the specific species, whereas
if only the species-group (i.e., Staphylococcus spp., Streptococcus
spp., or Candida spp.) relative qPCR was positive we identified
the microorganism(s) as belonging to the specific genus group.
Analytical Studies
We determined the LOD for the assay on isolates from 18
species of bacteria and 6 species of Candida, including species
representative of Staphylococcus spp. other than S. aureus,
Streptococcus spp. other than S. pneumoniae and S. pyogenes,
and Candida spp., using quantified spiked samples. We prepared
the sample matrix for spiking experiments using fresh microbial
suspensions to the appropriate density (CFU/ml) to obtain
replicate samples for testing. Then, we performed a Probit
analysis, which transforms the proportions of positive results
detected into a “probability unit” (or “probit”), using the
Analyze-it statistical analysis software addendum for Microsoft
Excel (Analyze-it Software Ltd., Leeds, UK). Briefly, we used
several dilutions of the microbial suspensions (CFU/ml) to
prepare eight replicates for each density. We plotted the probit
(y-axis) against the logarithm of the density (x-axis), and we
calculated the 95% LOD value, which was the density of each
microbial species in a sample that yielded positive detection 95%
of the time. We assessed the assay reproducibility (also known
as variability) using the same replicate experiments performed
to determine LOD, and we calculated the mean Cq values for
both target and internal control, along with the coefficient of
variation (% CV) as a variance measure. Finally, we performed
a carryover assessment by testing adjacent negative and highly
positive samples. Positives consisted of samples spiked with 106
or 107 CFU/ml of either blaKPC-positive Klebsiella pneumoniae
[KPC], vanA/vanB-positive Enterococcus faecium/Enterococcus
faecalis [VRE]), or both mecA-positive S. aureus [MRSA] and
Candida albicans.
Spiked and Clinical Blood Samples
We collected healthy volunteer blood samples, and we made
final dilutions of each of the aforementioned microorganisms for
generating blood samples spiked with cultured bacteria/Candida
species at a range of densities (107-101 CFU/ml). These samples
served to either optimize the amount of blood for clinical
testing or determine the LOD for each MicrobScan assay
target (as specified above), as well as to exclude any between-
target cross-reactivity. We used a set of 87 non-consecutive
fresh positive BCs (BacT/ALERT R© FA, FN, and PF Plus
bottles, bioMérieux, Marcy l’Étoile, France) obtained during
routine clinical microbiology at the Fondazione Policlinico
Universitario A. Gemelli IRCCS of Rome (Italy). These samples
were used to determine the analytical sensitivity and specificity
of the MicrobScan assay regardless of the density (CFU/ml)
of microorganisms cultured from the blood. Additionally, we
collected 229 EDTA whole blood (2–3ml) samples drawn
from prospectively consenting patients from September 2017
to August 2018 at the aforementioned Fondazione Policlinico
Universitario A. Gemelli IRCCS, using the same venipuncture
used for the BC samples. These samples were from patients for
whom physicians ordered BCs, as a part of the standard of care
per hospital protocol, due to the clinical suspicion of a BSI. Each
whole blood sample was used to assess the clinical sensitivity and
specificity of the MicrobScan assay; all samples were refrigerated
at 4◦C within 30min of collection and then frozen until analysis.
Microbiological Methods
We performed culture-based identification and antimicrobial
susceptibility testing of BSI isolates according to standard
laboratory procedures (Baron et al., 2013). Briefly, we incubated
all patient BC bottles that arrived at the clinical microbiology
laboratory in the BacT/Alert R© Virtuo R© system (bioMérieux)
at 37◦C for up to 5 days or until they signaled a positive result.
At the time bottles gave a positive signal or at the end of their
incubation period, we performed subcultures of the BC medium
on blood (for bacteria) or Sabouraud dextrose (for yeast) agar
plates to assess true-positive and true-negative detections.
We identified the bacteria and Candida isolates grown in the
blood by the MALDI BioTyper R© system (Bruker Daltonics,
Bremen, Germany) following the manufacturer’s instructions.
Then, we tested bacterial isolates for antimicrobial susceptibility
using the VITEK 2 R© automated system (bioMérieux), and we
used the 2017 EUCAST standards to interpret antimicrobial
susceptibility testing (AST) results (http://www.eucast.org/
fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_
7.1_Breakpoint_Tables.pdf). For bacterial isolates found to be
phenotypically resistant to extended-spectrum beta-lactamases,
oxacillin, or vancomycin, we performed PCR amplification of
the isolate DNA as previously described (Fiori et al., 2016) to
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4 November 2019 | Volume 9 | Article 389
Liotti et al. PCR Detection of Microbes in Blood
confirm the presence of blaKPC, mecA, or vanA/vanB genes,
respectively, in these isolates.
Data Analysis
We initially estimated the diagnostic performance of the
MicrobScan assay by calculating sensitivity, specificity, negative
predictive value (NPV), and positive predictive value (PPV)
compared to the BC method. To resolve discrepancies between
the MicrobScan assay and BC results, we used a synopsis of
clinical and/or laboratory data to identify the “true-infection”
cases among those that yielded false-positive MicrobScan assay
results. These data included microbiological results of BCs
from other BSI episodes and of cultures from other sites
of infection that were available within ± 7 days from the
index positive BC and consultation with the treating physician.
Based on this composite diagnostic criterion, we calculated
the overall agreement between the MicrobScan assay and BC
results. Finally, we compared the time to positive detection by
the MicrobScan assay with the time to culture-based species
identification (i.e., the time to BC positivity plus the time to result
by standard identification). Additionally, we used antimicrobial
therapy information to assess the potential influence of prior
antimicrobial use on the MicrobScan assay performance as
well as the potential impact of the MicrobScan assay results
on the antimicrobial treatment changes (i.e., escalation or
de-escalation) (Murri et al., 2018) in patient subgroups. We
performed statistical analyses using IBM SPSS software version
24.0 (Armonk, NY, USA), and we compared continuous variables
(expressed as the means ± SD) using Student’s t-test and
categorical variables (expressed as counts and percentages) using
Fisher’s exact test. Differences were considered to be statistically
significant at P < 0.05.
RESULTS
Analytical Sensitivity
We used qPCR primers designed to amplify unique sequences
in species-specific bacterial or Candida genes and in blaKPC,
mecA, or vanA/vanB antibiotic resistance genes representing
23 molecular targets in the MicrobScan assay (Table 1). We
combined multiple primers for the simultaneous recognition of
two, three, or four of the 23 targets in seven single-reaction (one
duplex, three triplex, and three quadruplex) wells. This in silico-
generated format allowed multiple fluorescently labeled TaqMan
probes to react with each of the corresponding PCR amplicons
in the well. First, we measured the LOD of the MicrobScan
assay with all targeted microorganisms (including KPC, MRSA,
and VRE) in both sterile phosphate-buffered saline and whole
bloodmatrices bymeans of singleplex qPCRs. All microorganism
LODs were similar between these two matrices, and the PCR
efficiency was >97% for each microorganism (see Table S1).
The assay had a mean (± SD) LOD of 15.6 ± 3.1 CFU for
bacteria (13.3 ± 1.6 for gram-negative and 18.5 ± 1.9 for gram-
positive) or Candida (16.5± 2.0) per ml of blood, and all targeted
microorganisms yielded LODs between 10 and 21 CFU/ml (see
Table S1). All the targets amplified with a Cq value between 22
and 38. The calibration curve indicated a linear dynamic range
of 106-101 CFU/ml. The primer pairs and probes in multiple
reactions did not significantly affect the sensitivity compared
with that of singleplex reactions. The assay variation during
the detection and identification of 3 × LOD spikes of the test
microorganisms ranged from +0.4 to +1.1 Cq values. Next, we
characterized the repeatability of the MicrobScan assay by testing
microorganisms at either 3× LOD or 10× LOD concentrations.
We spiked all the microorganisms into whole blood, and the
observed % CV among replicates was <30%, whereas the mean
Cq varied significantly depending on the 3 × LOD or 10 × LOD
concentration. Finally, among the independent possibilities to
observe carryover events based on the assay configuration, we did
not observe any carryover event.
Analytical Specificity
We evaluated the specificity of the multiplex qPCRs for the
identification of 20 microbes at the species level (including
Klebsiella spp., Staphylococcus spp., Streptococcus spp., and
Candida spp.) and for the detection of three (carbapenem,
methicillin, or vancomycin) resistance determinants. As shown
in Table S2, each of the six species-specific qPCRs correctly
detected DNA from the corresponding microbial species with
100% accuracy; the PCRs did not detect DNA from reference
ATCC strains or clinical isolates belonging to the different
species targeted or non-targeted by the MicrobScan assay. The
latter species comprised A. fumigatus, B. cepacia, C. striatum,
C. ramosum, C. neoformans, H. influenzae, L. pneumophila, M.
catarrhalis, N. meningitidis, P. vulgaris, and S. maltophilia. Each
resistance determinant-specific qPCR showed positive results
only with K. pneumoniae (ATCC R© BAA-1705TM), S. aureus
(ATCC R© 43300TM), E. faecium (ATCC R© 700221TM), and E.
faecalis (ATCC R© 51299TM) strains, which harbored the blaKPC,
mecA, vanA, or vanB genes, respectively. We did not observe
amplification with human DNA except in the sample control
(RNase-specific) well. Based on these findings, the MicrobScan
assay developed here had 100% specificity.
Direct Detection of Microbial Pathogens
From PBCB Samples
In the routine molecular diagnosis of BSIs, we and other
clinical microbiologists currently use PBCBs, as testing these
samples shortens the time to microbial species identification
(Fiori et al., 2014). We applied the MicrobScan assay to 87
samples consisting of aliquots of PBCBs, which yielded isolates
in mono- (N = 61) and polymicrobial (N = 26) growth
(Tables 2, 3). For monomicrobial cultures, we obtained 100%
detection matching the species identified by culture, except
for one sample positive for B. cepacia that the assay was not
designed to detect (Table 2). For the polymicrobial cultures,
the presence of multiple microorganisms did not prevent the
MicrobScan assay from detecting and identifying at least one of
the components of the mixed culture. Except for two samples
positive for C. striatum and C. ramosum that the assay was
not designed to detect, 18 (75.0%) of 24 samples had the
second and two of 18 had the third microorganism detected
by the MicrobScan assay (Table 3). While differences in the Cq
for single microorganism detection reflected differences in the
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TABLE 1 | Sequences of primers and probes used in the multiplex real-time PCRs.
Species* Target
gene
Primer
name
Primer sequence (5’−3’) Probe
name
Probe sequence (5
′
-3
′
)
†
Amplicon
size (bp)
Reference
GRAM-NEGATIVE SPECIES
Acinetobacter
baumannii
bap Aba-f CGCTGCAGCATCAAATCATG Aba-
Pro
Cy5-AGCACCTGCTGACACCACTCCACCA-
BHQ2
205 De Gregorio
et al., 2015Aba-r TGGGTCAACCGAGAAAGTTACG
Bacteroides
fragilis
leuB Baf-f CACTTGACTGTTGTAGATAAAGC Baf-
Pro
FAM-TGTGCTTGCTTCCAGTCGTCTATG-
BHQ1
135 Papaparaskevas
et al., 2013Baf-r CATCTTCATTGCAGCATTATCC
Enterobacter
aerogenes
omp35 Ena-f CCCATGCTTCAGCTTTGTCA Ena-
Pro
TxRd-CGTTGCCGTCACGTTTCTGGTCAA-
BHQ2
74 van der Zee
et al., 2016Ena-r CTGCAGGTTACGCTAACTCCAA
Enterobacter
cloacae
complex
apbC Enc-f ACAAAGGAGTCGGGATGAGTTC Enc-
Pro
FAM-CAATCCCAGGCCAAATCACCGG-BHQ1 65 van der Zee
et al., 2016
Enc-r CGACCATTGCTCGTAAGGCT
Escherichia
coli
16S rRNA Eco-f CATGCCGCGTGTATGAAGAA Eco-
Pro
FAM-
TATTAACTTTACTCCCTTCCTCCCCGCTGAA-
BHQ1
96 van den Brand
et al., 2014Eco-r CGGGTAACGTCAATGAGCAAA
Klebsiella
spp.
rhaA–rhaD
operon
Kle-f AACCAGGCGTCGATAAT Kle-
Pro
HEX-ACAGGAAAGACAAGACTATGCAGACC-
BHQ1
107 van den Brand
et al., 2014Kle-r GTTTACGGCGCAATCC
Proteus
mirabilis
hns Pmi-f GCACGTTTAGCACGACCAGTT Pmi-
Pro
TxRd-CGCCAGCAGCTTCAAGCAGGTCA-
BHQ2
71 van der Zee
et al., 2016Pmi-r TGCCGATGGTATTGATCCAA
Pseudomonas
aeruginosa
phzE Pae-f GCCGAGGTCATGGAATTC Pae-
Pro
HEX-CGACAACCGCAAGGAAGCCGA-BHQ1 89 van den Brand
et al., 2014Pae-r ATCCGCGCCATCATCTTC
Serratia
marcescens
gyrB Sma-f GACCGTGAAGACCACTTCCATTAC Sma-
Pro
Cy5-
CGATCCACCCGAACGTGTTCTACTTCTC-
BHQ2
125 van den Brand
et al., 2014Sma-r ACGCCGATGTCGTCTTTCAC
GRAM-POSITIVE SPECIES
Enterococcus
faecalis
groESL Efs-f TGATGCCCGCGTTCATTTA Efs-
Pro
Cy5-AAACCAAATCGGCGAAACAACGTCTG-
BHQ2
77 Fukumoto et al.,
2015Efs-r CGTTCTTGTAATTTTTCACGATCAA
Enterococcus
faecium
groESL Efm-f GTATCAAGATCGTTGTTCGTGCTT Efm-
Pro
TxRd-AGAAGAACCAATTCGTCAAATCGCTG-
BHQ2
74 Fukumoto et al.,
2015Efm-r CTGATCCTTCATAACCAGCGTTT
Staphylococcus
aureus
spa Sau-f CAGCAAACCATGCAGATGCTA Sau-
Pro
FAM-AAAGCTCAAGCATTACCAGAAACTG-
BHQ1
101 This study
Sau-r CGCTAATGATAATCCACCAAATACA
Staphylococcus
spp.
tuf Sta-f CCAACWCCAGAACGTGAYTCTG Sta-
Pro
HEX-
ACAGGCCGTGTTGAACGTGGKCAAATCAA-
BHQ1
222 van den Brand
et al., 2014Sta-r GTTRTCACCAGCTTCAGCGTART
Streptococcus
pneumoniae
lytA Spn-f ACGCAATCTAGCAGATGAAGCA Spn-
Pro
HEX-TGCCGAAAACGCTTGATACAGGGAG-
BHQ1
74 Gadsby et al.,
2015Spn-r TCGTGCGTTTTAATTCCAGCT
Streptococcus
pyogenes
sdaB Spy-f GGRACACGTACCCAAAATGTAGGA Spy-
Pro
TxRd-CGTGACCAAAAAGGCGGCATGC-
BHQ2
73 Fukumoto et al.,
2015Spy-r TCTTGAGCTCTTTGTTCGGTRTAG
Streptococcus
spp.
16S rRNA Str-f ATCCTTWCTAAAGAAGAAG Str-
Pro
FAM-CTCCATTCTTCAACAACTACCG-BHQ1 117 This study
Str-r GTTATCACCAGGCATWAC
FUNGAL SPECIES
Candida
albicans
5.8S rRNA Calb-f GGTTTGCTTGAAAGACGGTA Calb-
Pro
Cy5-TTACCGCCGCAAGCAATGTT-BHQ2 109 This study
Calb-r AGTTTGAAGATATACGTGGTA
Candida
krusei
ITS1, 5.8S
rRNA, ITS2
Ckru-f CCTGTTTGAGCGTCATTTCC Ckru-
Pro
HEX-AGCTGGCCGAGCGAACTAGACTTTT-
BHQ1
219 Metwally et al.,
2007Ckru-r CCTGCTTTGAACACTCTAA
Candida
glabrata
ITS1, 5.8S
rRNA, ITS2
Cgla-f CCTGTTTGAGCGTCATTTCC Cgla-
Pro
FAM-TAGGTTTTACCAACTCGGTGTTGAT-
BHQ1
229 Metwally et al.,
2007Cgla-r AGCACGCACAAAACACTCACTTAT
Candida spp. 18S rRNA Can-f TAGTTGGTGGAGTGATTTGTCTG Can-
Pro
TxRd-AACCTACTAAATAGTGCTGCTAGCCAT-
BHQ2
159 This study
Can-r TAAGGGCATCACAGACCTGTTA
ANTIMICROBIAL-RESISTANT SPECIES
Carbapenem-
resistant
blaKPC Kpc-f CGCAACTGTAAGTTACCG Kpc-
Pro
Cy5-CCACTGTGCAGCTCATTCAAGG-BHQ2 187 Zheng et al.,
2013Kpc-r CATGCCTGTTGTCAGATA
(Continued)
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TABLE 1 | Continued
Species* Target
gene
Primer
name
Primer sequence (5’−3’) Probe
name
Probe sequence (5
′
-3
′
)
†
Amplicon
size (bp)
Reference
Methicillin-
resistant
mecA Mec-f AAAGAACCTCTGCTCAACAAGT Mec-
Pro
HEX-
CCAGATTACAACTTCACCAGGTTCAACT-
BHQ1
88 Thomas et al.,
2007Mec-r TGTTATTTAACCCAATCATTGCTGTT
Vancomycin-
resistant
vanA VanA-f TCTTAATTGAGCAGGCTGT VanA-
Pro
FAM-TACCGCACAACCGACCTCACA-BHQ1 82 This study
VanA-r CACCTCGCCAACAACTA
vanB VanB-f GATAGAAGCAGCAGGACAAT VanB-
Pro
FAM-CGCAGCCGACCTCACAGC-BHQ1 109 This study
VanB-r CGCCGACAATCAAATCATC
Duplex, triplex, or quadruplex reactions were optimized to include Taqman probes, together with each relative primer (forward [f] and reverse [r]) pair, in single wells, which allowed
the detection of the DNA from two, three, or four of the 23 listed molecular targets. The best combinations were Staphylococcus aureus and Staphylococcus spp.; blaKPC, mecA,
and vanA/vanB; Klebsiella aerogenes, Enterobacter cloacae complex, and Klebsiella spp.; Enterococcus faecalis, Enterococcus faecium, and Streptococcus spp.; Acinetobacter
baumannii, Escherichia coli, Pseudomonas aeruginosa, and Proteus mirabilis; Bacteroides fragilis, Serratia marcescens, Streptococcus pyogenes, and Streptococcus pneumoniae;
Candida albicans, Candida glabrata, Candida krusei, and Candida spp. As a result, the MicrobScan assay consisted of eight distinct wells (seven with multiplex organism-specific
reactions and one with a human RNase-coding gene-based control) per sample. * Including Klebsiella pneumoniae, Klebsiella oxytoca, and Klebsiella ozaenae (Klebsiella spp.); S. aureus,
Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus haemolyticus, Staphylococcus lugdunensis, and Staphylococcus warneri (Staphylococcus spp.); Streptococcus
agalactiae, Streptococcus anginosus, Streptococcus gallolyticus, Streptococcus gordonii, Streptococcus oralis, Streptococcus mitis, Streptococcus parasanguinis, Streptococcus
pneumoniae, and Streptococcus pyogenes (Streptococcus spp.); and Candida albicans, Candida parapsilosis, Candida orthopsilosis, and Candida tropicalis (Candida spp.).
†
All probes were labeled with a reporter dye (i.e., cyanine5 [Cy5], 6-carboxyfluorescein [FAM], hexachlorofluorescein [HEX], or Texas Red [TxRd]) at the 5’-end and with a quencher (i.e.,
Black Hole Quencher 1 [BHQ1] or Black Hole Quencher 2 [BHQ2]) at the 3’-end.
TABLE 2 | Results for 61 positive blood culture broth (PBCB) samples with
monomicrobial growth tested by the MicrobScan assay.
PBCB testing MicrobScan assay testing
Species identified (no. of isolates) Positive Cq
Acinetobacter baumannii (2) 2/2 17.1 ± 0.5
Burkholderia cepacia* (1) 0/1 –
Candida albicans (1) 1/1 18.7
Candida glabrata (1) 1/1 18.8
Candida species (2) 2/2 18.9 ± 1.7
Coagulase-negative staphylococci (4)
†
4/4 17.2 ± 2.1
Enterobacter cloacae (1) 1/1 18.3
Enterococcus faecalis (2) 2/2 12.5 ± 0.2
Enterococcus faecium (3) 3/3 14.3 ± 0.4
Escherichia coli (11) 11/11 17.9 ± 0.6
Klebsiella species (10) 10/10 17.2 ± 0.9
Proteus mirabilis (1) 1/1 18.6
Pseudomonas aeruginosa (4) 4/4 18.9 ± 1.0
Serratia marcescens (2) 2/2 18.0 ± 1.1
Staphylococcus aureus (12) 12/12 19.8 ± 0.3
Streptococcus species (4)
†
4/4 17.2 ± 4.3
Total (61) 60/61
*Not included in the target species panel.
†
Including isolates identified as S. epidermidis (among coagulase-negative
staphylococci) or S. gallolyticus, S. gordonii, S. oralis, and S. parasanguinis (among
Streptococcus species).
CFU/ml of single microorganisms concomitantly present in a
PBCB sample (i.e., a lower Cq corresponded to a higher CFU/ml),
failures to detect the second microorganism in 6 (25.0%) of
24 samples did not always reflect differences in the CFU/ml
between concomitant microorganisms. Expectedly, failures often
occurred in samples containing two (or three) microorganisms
from species that the assay detects in the same reaction well
(see Table S2). One example was A. baumannii (CFU/ml, 2 ×
108) that grew in culture together with P. aeruginosa (1 × 106
CFU/ml), which the assay failed to detect (Table 3). Another
example was S. epidermidis (1.5 × 108 CFU/ml) that grew in
culture together with A. baumannii (1 × 106 CFU/ml), which
the assay also failed to detect (Table 3). In one case, PCR
primers and probes for A. baumannii and P. aeruginosa worked
in the same reaction; in the other case, the primers for A.
baumannii and S. epidermidis did not work in the same reaction
(see Table S2). Interestingly, in two samples both positive for
S. aureus and a Staphylococcus species other than S. aureus
(S. capitis and S. epidermidis, respectively), the species-specific
probes yielded two sharp fluorescence signals that strongly
suggested the concomitant presence of two staphylococci. These
samples were clearly distinguished from the samples only
containing S. aureus that, indeed, gave a strong signal with the S.
aureus-specific probe and a weak signal with the probe specific
for Staphylococcus species other than S. aureus. Additionally,
both the laboratory reference method and the MicrobScan assay
detected a microorganism associated with one of the antibiotic
resistance determinants targeted by the MicrobScan assay. Thus,
in 100% of samples (28/28), the reference method results and
those of the MicrobScan assay were fully concordant (9/9 blaKPC,
18/18 mecA, and 1/1 vanA/vanB). Of 18 mecA genes detected,
12 were from S. aureus, and six were from coagulase-negative
staphylococci (5 S. epidermidis and 1 S. hominis).
Direct Detection of Microbial Pathogens
From Blood Samples
We conducted a clinical evaluation of the MicrobScan assay
using whole-blood samples from patients with a suspected
BSI who were hospitalized at the Fondazione Policlinico
Universitario A. Gemelli IRCCS of Rome, Italy, during
September 2017–August 2018. To evaluate the diagnostic
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TABLE 3 | Results for 26 positive blood culture broth (PBCB) samples with polymicrobial growth tested by the MicrobScan assay.
PBCB testing MicrobScan assay testing
Species identified Microbial concentration (CFU/ml) Positive detection for indicated species Cq for single detection
Species 1 Species 2 Species 3 Species 1 Species 2 Species 3
A. baumannii/P. aeruginosa 1.3 × 108 1.1 × 107 – A. baumannii 17.89 – –
A. baumannii/P. aeruginosa 2.0 × 108 1.0 × 106 – A. baumannii 17.02 – –
A. baumannii/S. epidermidis 1.2 × 108 1.2 × 108 – A. baumannii/Staphylococcus spp. 17.11 17.21 –
A. baumannii/S. epidermidis 1.7 × 108 1.1 × 108 – A. baumannii/Staphylococcus spp. 17.50 17.98 –
C. albicans/K. oxytoca/E. cloacae 3.0 × 107 1.5 × 106 1.2 × 106 C. albicans/Klebsiella spp./E. cloacae complex 18.46 22.42 23.71
C. albicans/S. epidermidis 1.2 × 108 1.2 × 106 – C. albicans/Staphylococcus spp. 17.95 22.11 –
C. parapsilosis/S. capitis 1.4 × 107 1.2 × 107 – Candida spp./Staphylococcus spp. 18.94 19.31 –
E. faecalis/A. baumannii 1.3 × 108 3.0 × 106 – E. faecalis/A. baumannii 16.40 22.90 –
E. faecalis/C. albicans 1.2 × 108 1.2 × 106 – E. faecalis/C. albicans 17.97 21.20 –
E. faecalis/S. aureus 1.3 × 109 1.2 × 108 – E. faecalis/S. aureus 14.88 17.02 –
E. faecium/K. oxytoca 1.3 × 108 1.5 × 107 – E. faecium/Klebsiella spp. 17.94 20.63 –
E. faecium/S. aureus/S. capitis 1.7 × 109 1.9 × 108 1.2 × 107 E. faecium/S. aureus/Staphylococcus spp. 14.60 17.29 20.34
E. coli/K. pneumoniae/P. aeruginosa 1.4 × 108 1.6 × 107 1.2 × 105 Escherichia coli/Klebsiella spp. 16.28 20.77 –
K. pneumoniae/E. cloacae 2.1 × 108 1.4 × 106 – Klebsiella spp. 17.32 – –
K. pneumoniae/E. coli 3.0 × 109 1.7 × 105 – Klebsiella spp. 18.74 – –
K. pneumoniae/P. aeruginosa 2.1 × 108 1.9 × 107 – Klebsiella spp./P. aeruginosa 18.25 19.22 –
K. pneumoniae/S. hominis 2.1 × 108 1.5 × 107 – Klebsiella spp./Staphylococcus spp. 18.66 19.02 –
P. mirabilis/S. aureus 1.3 × 108 1.0 × 107 – P. mirabilis/S. aureus 18.07 20.27 –
P. aeruginosa/C. striatum* 1.1 × 108 2.0 × 106 – P. aeruginosa 18.04 – –
S. aureus/P. aeruginosa 2.8 × 107 1.7 × 107 – S. aureus/P. aeruginosa 21.15 21.35 –
S. aureus/S. salivarius 1.3 × 108 2.5 × 106 – S. aureus/Streptococcus spp. 18.56 23.38 –
S. aureus/S. anginosus 1.3 × 108 1.8 × 107 – S. aureus/Streptococcus spp. 20.24 21.28 –
S. epidermidis/A. baumannii 1.5 × 108 1.2 × 106 – Staphylococcus spp. 17.59 – –
S. epidermidis/S. aureus 1.7 × 108 2.0 × 107 – Staphylococcus spp./S. aureus 19.65 20.83 –
S. hominis/S. mitis 1.3 × 108 1.2 × 106 – Staphylococcus spp. 17.72 – –
S. anginosus/C. ramosum* 1.4 × 108 1.5 × 108 – Streptococcus spp. 17.46 – –
*Not included in the target species panel.
accuracy of the assay, we compared the MicrobScan assay
results with those of the BCs simultaneously performed as a
standard diagnostic method (Table 4). Of the 229 samples tested,
four samples were positive in culture for microorganisms not
targeted by the MicrobScan assay (i.e., Morganella morganii,
N. meningitidis, Bacteroides thetaiotaomicron, and Listeria
monocytogenes). Overall, sensitivity and specificity were 72.1
and 86.6%, respectively. The remaining 225 samples (133 from
adult patients and 92 from pediatric patients) yielded 56
organism detections (52 single and 4 multiple) by the assay,
whereas BCs yielded 39 (35monomicrobial and 4 polymicrobial).
The polymicrobial BCs consisted of three cultures with two
microorganisms and one culture with three microorganisms.
The MicrobScan assay matched 31 of the 39 positive detections
obtained by culture (79.5% agreement) and detected an
additional 25 microorganisms in culture-negative samples (15
from pediatric patients and 10 from adult patients) (Table 4). The
MicrobScan assay-positive, culture-negative detections regarded
species such as E. coli (N = 8), S. aureus (N = 6), and S.
pneumoniae (N = 4) in most cases, or species such as C.
glabrata (N = 1) and E. aerogenes (N = 1). In all six samples
with mecA-positive microorganism detection (4 S. aureus and
2 S. epidermidis), the results from the MicrobScan assay were
concordant with the results obtained by the laboratory reference
method. To support the MicrobScan assay-positive, culture-
negative detection results, we used “clinical indications” of
infection, which consisted of detecting the same microorganisms
and identifying them as causal pathogens in concomitant
analyses of sterile fluids other than blood, respiratory tract
fluids or aspirates, and/or urinary tract samples from the
same patients. By applying this criterion, the sensitivity and
specificity increased to 86.4 and 97.0%, respectively, suggesting
that the discordant results for 20 MicrobScan assay-positive/BC-
negative samples (13 from pediatric patients and 7 from adult
patients) were true positives (Table 4). Notably, 11 (84.6%)
of 13 and 4 (57.1%) of 7, accounting for a total of 75.0%
(15/20), of the patients were receiving antimicrobial therapy.
Overall, 13 MicrobScan assay results remained discordant, five
of which represented overdetection (2 E. coli, 1 E. faecalis, 1
C. albicans, and 1 C. glabrata) and eight missed detections (2
E. faecalis, 1 K. pneumoniae, 1 S. aureus, 1 S. parasanguinis,
and 3 Staphylococcus species other than S. aureus). In addition
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TABLE 4 | Performance of the MicrobScan assay in whole-blood samples from
patients with suspected bloodstream infections.
MicrobScan assay results evaluated
according to the criterion of
Blood
culture
Clinically and/or
laboratory-documented infection
Total blood samples
tested (N = 225)
Matched positives, n
31 51
Matched negatives, n 161 161
MicrobScan assay
overdetection, n
25 5
MicrobScan assay
missed detections, n
8 8
Overall agreement, % 85.3 94.2
Sensitivity, % 79.5 86.4
Specificity, % 86.6 97.0
PPV, % 55.3 91.1
NPV, % 95.3 95.3
Data from either blood culture testing or clinical and/or laboratory findings were used to
evaluate the MicrobScan assay results.
to S. parasanguinis and one E. faecalis grown in pediatric
bottles, the missed microorganisms included three coagulase-
negative staphylococci, which were likely contaminants, and one
E. faecalis (vancomycin susceptible), which was detected after
47.19 h of incubation and for which the clinical relevance could
not be determined from the patient’s clinical course. Two other
microorganisms, one K. pneumoniae (carbapenem susceptible)
and one S. aureus (methicillin susceptible), represented missed
detections that were not explainable as contaminants or not
clinically relevant. Finally, the mean (± SD) times to positive
results by the MicrobScan assay and the BC method (including
species identification) were 5.3 ± 0.2 h and 17.8 ± 12.1 h for
bacterial species and 5.3 ± 0.2 h and 22.7 ± 10.1 h for Candida
species, respectively (P <0.001, for all comparisons). The mean
(± SD) times to negative results by the MicrobScan assay and
the BC method were 5.1 ± 0.1 h and 120.0 ± 0.0 h, respectively
(P < 0.001).
Clinical Value Assessment
We assessed the MicrobScan assay from a strictly clinical
standpoint by reviewing the records of the 31 BSI patients with
positive detections by both the MicrobScan assay and the BC
method. Based on the BC results, the physicians decided to
change the antimicrobial therapy initiated at the BSI onset in 20
(64.5%) patients [mean (± SD) time to change, 21.3 ± 13.2 h].
Five patients had their antimicrobial therapy changed the same
day (9.8 h ± 5.0 h), and 15 had their antimicrobial therapy
changed on the subsequent days (25.1± 12.9 h) of BC collection.
The initial antimicrobial therapy was escalated in 12 patients
and de-escalated in eight patients. In the remaining 11 (35.5%)
patients, the initial antimicrobial therapy was unchanged. Based
on the MicrobScan assay results, the physicians could have
escalated or de-escalated the antimicrobial therapy initiated at the
BSI onset in the 20 patients with a mean (± SD) time of 11.6 ±
5.2 h. Furthermore, we assessed the impact of prior antimicrobial
use on the MicrobScan assay performance in comparison with
the BC method for all 225 cases (88 with and 137 without
antimicrobials) studied. The subgroup analysis of the BC results
showed that prior antimicrobial use was significantly associated
with culture-negative but MicrobScan-positive cases compared
with cases in which both culture and MicrobScan results were
negative [72.0% (18/25) and 37.3% (60/161), respectively; P
<0.002]. Consistently, the subgroup analysis of the MicrobScan
results showed that a previous antimicrobial use was significantly
associated with MicrobScan-positive but culture-negative cases
compared with cases in which both culture and MicrobScan
results were positive [72.0% (18/25) and 29.0% (9/31), P< 0.003].
DISCUSSION
We show that the MicrobScan assay is capable of reliably
identifying bacterial and fungal (Candida) pathogens directly in
whole-blood samples from patients with a suspected BSI. The
assay combines automated sample preparation with multiplex
qPCR for selected targets within single-reaction wells, and
detects 16 bacteria and 4 fungi as well as 3 antibiotic resistance
determinants in ∼5 h. Interestingly, in 31 (79.5%) of the
39 culture-documented BSI cases with concordant positive
MicrobScan assay results, 20 patients could have benefited
from timely appropriate antimicrobial therapy. In these patients,
physicians changed the initial antimicrobial treatment at 21.3 ±
13.2 h following the notification of a BC result. These changes
could have occurred 9.7 ± 8.0 h earlier in the case of a
MicrobScan assay result notification. Nevertheless, assay failures
occurred in eight of 39 (20.5%) samples, which is of concern. We
hypothesized possible reasons for this lack of success, such as the
uneven distribution of bacterial/Candida species within clinical
samples or the errors relating to the sensitivity and specificity of
qPCRs. Clinically appropriate management of sepsis and septic
shock includes performing BCs before initiating antimicrobial
therapy, with at least two BC pairs (using both aerobic and
anaerobic bottles) collected per BSI episode (Rhodes et al., 2017).
Among the eight cases with MicrobScan assay-negative results,
we detected microorganisms (all in monomicrobial growth) in
only one of the BC pairs obtained from the patients. Considering
the clinical significance of four of these organisms questionable,
the rate of false-negative results by the assay decreased to 10.2%
(4/39), which is of less concern.
We sought to rule out any impairment in the accurate
quantification of multiple targets in a single reaction by
demonstrating that the assay efficiency and the LOD were the
same as when the reactions ran in a singleplex manner. This
issue is particularly crucial when amplifying targets of low relative
abundance together with targets of high relative abundance
(Bustin et al., 2009). We tested the MicrobScan assay on
polymicrobial PBCB samples before blindly using it directly on
whole-blood samples. Expectedly, the qPCR detection efficiency
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was good in all 24 of the evaluable 26 polymicrobial PBCBs. Two
PBCBs grew, as a secondmicroorganism, species (i.e., C. striatum
and C. ramosum) not included in the target species panel of the
MicrobScan assay. Failure to detect the second microorganism
occurred in six samples and, surprisingly, two of undetected
microorganisms were P. aeruginosa. This might be attributed
to quantitative differences between the two microorganisms
present in the same PBCB sample, especially when the two
microorganisms had to be detected in the same reaction.
Nevertheless, it is improbable that such high concentrations of
qPCR template represent the microbial density levels in infected
patient’s blood samples before their “amplification” in culture,
as in PBCBs. The microbial density in blood is generally very
low, particularly for cases of invasive candidiasis that encompass
candidemia and deep-seated candidiasis (Clancy and Nguyen,
2013). Indeed, the LOD for BCs is comparable to that of PCR-
based methods, at least in invasive Candida infections (Arvanitis
et al., 2014).
Using BCs as a comparator may not be appropriate due
to limitations including sensitivity. We know that a number
of factors can influence the diagnostic accuracy of BCs, and
antimicrobial therapy prior to blood sampling is one such
factor (among others) (Lamy et al., 2018). However, PCR-
based detection of bacteria and fungi in culture-negative clinical
samples, especially obtained from patients on antimicrobial
therapy, continues to create a clinical interpretation challenge
(Farrell et al., 2013). MicrobScan assay-positive/culture-negative
results may promote the inappropriate antimicrobial treatment
of patients who are unlikely to have bacteremia or candidemia,
which would inadvertently lead to unintended consequences
for institutional efforts to optimize antimicrobial prescription
practices (Murri et al., 2018). Among the 225 patients studied, 88
(39.1%) were under antimicrobial treatment at the time a blood
sample was collected for testing with the MicrobScan assay. We
showed that prior antimicrobial exposure did not adversely affect
the performance of the MicrobScan assay. Eighteen (23.1%) of 78
patients with a negative BC result and nine (90.0%) of 10 patients
with a positive BC result had positive detection results in the
MicrobScan assay.
We performed an in-depth culture-based analysis of the 25
patient cases where the MicrobScan assay identified additional
microorganisms. We found that 20 of 25 microorganisms were
isolated and identified as causal pathogens from the primary
cultures of clinical specimens obtained from the same patients
almost concomitantly with the blood samples for MicrobScan
assay testing. In all 20 cases, the microorganism was the same,
thus reflecting the source of infection, and interestingly, 15
(75.0%) of the 20 patients were receiving antimicrobial therapy.
More interestingly, the MicrobScan assay mirrors what seen with
the T2 magnetic resonance-based method, from which it differs
technologically (T2 Biosystems, Lexington, Massachusetts, USA;
www.t2biosystems.com). A recent multicenter study by Nguyen
et al. (2019) showed that 13.0% of the patients studied had BC
and T2Bacteria results positive for the six T2Bacteria-targeted
bacterial species. Among negative BCs with a positive T2Bacteria
result, 60.0% of them were associated with probable or possible
BSIs (Nguyen et al., 2019). In our previous evaluation of the
T2Bacteria R© Panel (De Angelis et al., 2018), we found 89.0%
sensitivity and 98.0% specificity among patients with positive BCs
for the 6 bacterial species or fulfilling the criteria for infection
(named CI, but similar to those specified above). Consistent
with the present study, T2 Bacteria-positive/BC-negative results
were significantly more likely to occur among patients receiving
antimicrobial therapy (P < 0.001). Taken together, these findings
show that the MicrobScan assay may be particularly worth using
in conjunction with cultures and during antimicrobial therapy.
In summary, the MicrobScan assay has the potential to
rapidly exclude and identify diverse bacterial and Candida
BSIs, including cases that the standard BCs may not detect.
The spectrum of molecular targets is restricted to common
infecting pathogens and antimicrobial resistance-associated
genes. However, we noticed that the MicrobScan assay targets
cover ∼92% of the BSIs diagnosed in our clinical microbiology
laboratory (Fiori et al., 2016), which yet excludes clinically
relevant species such as N. meningitidis or H. influenzae.
Theoretically, small laboratories without experience in molecular
detection platforms and techniques may be suitable users.
In practice, it is mandatory that clinical microbiologists
interpret the MicrobScan assay results in the context of clinical
and other laboratory findings, as with current culture-based
identifications. Thus, we believe that large laboratories can better
supply both expertise and additional information. Carefully
designed clinical studies are therefore necessary to establish
the role that the MicrobScan assay may play in the future
microbiology laboratory.
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